EGFR and glioblastoma: Moreover, as this evidence supports that EGFR amplification, KI67 expression, and IDH status are widely used biomarkers for predicting the outcome of GBM patients [29] and CHST12 has the potential to link them, we considered that CHST12 may have significant clinical value in the development of GBM.